A 42-year-old nulliparous woman with a known 6 cm intramural fibroid uterus presents with severe dysmenorrhoea and heavy menstrual bleeding unresponsive to 6 months of levonorgestrel intrauterine system (LNG-IUS) therapy. She is not interested in future pregnancy. Pelvic ultrasound confirms the fibroid remains 6 cm with no change in size. Her haemoglobin is now 8.5 g/dL despite iron supplementation. What is the most appropriate next step in management?

Explanation

## Clinical Context: Failed Medical Management **Key Point:** This patient has **failed first-line medical therapy** (LNG-IUS × 6 months with no fibroid shrinkage or symptom relief) and has developed **significant anaemia** (Hb 8.5 g/dL). She is now a candidate for **surgical intervention**. ## Decision-Making Algorithm ```mermaid flowchart TD A[Failed medical therapy<br/>Hb 8.5 g/dL]:::outcome --> B{Fertility desired?}:::decision B -->|Yes| C[Myomectomy]:::action B -->|No| D{Severe anaemia<br/>or large fibroid?}:::decision D -->|Yes| E[GnRH agonist × 3 months<br/>+ iron/transfusion]:::action D -->|No| F[Direct hysterectomy]:::action E --> G[Hysterectomy]:::action F --> H[Symptom relief]:::outcome G --> H ``` ## Why GnRH Agonist Before Hysterectomy? ### Preoperative GnRH Agonist Benefits | Benefit | Mechanism | Clinical Impact | | --- | --- | --- | | **Fibroid shrinkage** | Hypo-oestrogenic state; fibroid involution | 40–60% size reduction; easier surgical access | | **Endometrial atrophy** | Reduced endometrial thickness | Decreased intraoperative bleeding | | **Haemoglobin recovery** | Cessation of menstrual blood loss | Preoperative Hb optimisation; reduced transfusion risk | | **Myometrial recovery** | Reduced vascularity and oedema | Shorter operative time; less blood loss | **High-Yield:** In a patient with **severe anaemia (Hb < 9 g/dL)** and **large fibroid (≥ 6 cm)** requiring hysterectomy, **3 months of GnRH agonist** is standard preoperative preparation. This allows Hb recovery and reduces operative morbidity. ## Why Not Myomectomy? - Patient is **nulliparous and not seeking fertility** — hysterectomy is definitive and avoids recurrence risk - Myomectomy in a 42-year-old nulliparous woman with failed medical therapy and severe anaemia is not justified - Intramural fibroids (6 cm) carry higher myomectomy morbidity (uterine rupture in future pregnancy, though not applicable here) ## Why Not Continue LNG-IUS or Add Tranexamic Acid? **Key Point:** After **6 months of adequate LNG-IUS therapy with no fibroid shrinkage or symptom improvement**, continuing medical management is futile and delays definitive treatment. The patient has **failed first-line therapy** and has **progressive anaemia** — she needs surgery. Transexamic acid is an **adjunctive antifibrinolytic**, not primary therapy. It may reduce bleeding by 20–30% but cannot replace failed hormonal therapy. ## Clinical Pearl **Warning:** Do not confuse **adjunctive medical therapy** (tranexamic acid, NSAIDs, iron) with **primary medical therapy** (OCP, LNG-IUS, GnRH agonist). Once primary therapy has failed, adjunctive agents alone are insufficient — surgery is indicated. ## Preoperative Optimisation Protocol 1. **GnRH agonist** (e.g., leuprolide 3.75 mg IM monthly × 3 doses) 2. **Iron supplementation** (ferrous sulphate 200 mg BD) 3. **Consider transfusion** if Hb drops below 7 g/dL 4. **Reassess Hb at 3 months** before hysterectomy 5. **Hysterectomy** (total abdominal or laparoscopic, depending on uterine size and surgeon expertise) [cite:Jeffcoate's Principles of Gynaecology 16e Ch 14; RCOG Green-top Guideline 64: Management of Uterine Fibroids]